Kinase inhibitors in oncology. What is new?

被引:0
|
作者
Riedmann, K. [1 ]
Bassermann, F. [1 ,2 ]
Jost, P. J. [1 ,2 ]
机构
[1] Tech Univ Munich, Med Klin Hamatol & Internist Onkol 3, Munich, Germany
[2] Deutsch Krebsforsch Zentrums Heidelberg DKFZ, Partnerstandort Munchen, DKTK, Munich, Germany
来源
INTERNIST | 2019年 / 60卷 / 05期
关键词
Protein kinase inhibitors; adverse effects; Protein-tyrosine kinases; Molecular targeted therapy; Leukemia; myeloid; Carcinoma; non-small-cell lung; FOLLOW-UP; BCR-ABL; IMATINIB; THERAPY; CABOZANTINIB; SORAFENIB; IBRUTINIB;
D O I
10.1007/s00108-019-0577-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Kinase inhibitors are now among the most important drugs in targeted therapy and are used in particular for the treatment of different tumor entities. Since many kinase inhibitors inhibit various tyrosine kinases efficiently but not specifically, they are often characterized by their versatile use in awide variety of entities and diseases. The diverse use of this group of drugs, as well as the challenge of their side-effect profile, continues to make kinase inhibitors the subject of numerous clinical studies. The following article provides an overview of recent new approvals in the field of kinase inhibitors and shows their importance for oncological therapy.
引用
收藏
页码:540 / 544
页数:5
相关论文
共 50 条
  • [1] Meeting the needs of nurses new to oncology.
    Glemser, Elizabeth
    Lindsey, Susan
    Andres, Melissa
    ONCOLOGY NURSING FORUM, 2007, 34 (02) : 561 - 561
  • [2] Nephrotoxicity due to immune checkpoint inhibitors in rural oncology.
    Leon, Chady Abboud
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] Delirium in oncology.
    Reich, MG
    Razavi, D
    BULLETIN DU CANCER, 1996, 83 (02) : 115 - 128
  • [4] Integrative Oncology.
    Bauer, Brent A.
    PSYCHO-ONCOLOGY, 2009, 18 (12) : 1333 - 1334
  • [5] Integrative Oncology.
    不详
    ONCOLOGY NURSING FORUM, 2009, 36 (02) : 244 - 244
  • [6] New trends in CT. Applications in oncology.
    Coulomb, M
    Ferretti, G
    Ranchoup, Y
    Blanc, F
    Albano, G
    BULLETIN DU CANCER, 1995, 82 : S536 - S543
  • [7] Cardenolides: old drugs with new applications in oncology.
    Kiss, Robert
    Mijatovic, Tatjana
    Van Quaquebeke, Eric
    Darro, Francis
    CANCER RESEARCH, 2006, 66 (08)
  • [8] New challenges in medical oncology. From medical oncology to oncological medicine
    Durand, JP
    Goldwasser, E
    ANNALES DE MEDECINE INTERNE, 2003, 154 (03): : 131 - 132
  • [9] The new mutational model in oncology. What changes in welfare, clinical practice, research, and regulatory procedures?
    Normanno, N.
    Curigliano, G.
    Jommi, C.
    Martini, N.
    Marchetti, A.
    Marchetti, P.
    Pedrini, A.
    Pruneri, G.
    ANNALS OF ONCOLOGY, 2019, 30
  • [10] Raf kinase inhibitors in oncology
    Strumberg, D
    Seeber, S
    ONKOLOGIE, 2005, 28 (02): : 101 - 107